Abstract:
En
|
Text:
En
|
PDF:
En
Abstract Hepatic injury has been documented in patients with coronavirus disease 2019 (COVID-19). However, pharmacotherapy can frequently impact liver alterations, given the known hepatotoxic potential of drugs not effective to treat COVID-19. The objective of the present study was to evaluate reports of suspected liver reactions to drugs used for treating COVID-19, compare their use for other indications among patients with COVID-19, and assess possible interactions between them. We obtained reports on drugs used to treat COVID-19 (tocilizumab, remdesivir, hydroxychloroquine, and/or lopinavir/ritonavir), registered on June 30, 2020, from the Food and Drug Administration Adverse Event Reporting System (FAERS) Public Dashboard. We then analyzed the risk of developing liver events with these drugs by calculating the reported odds ratios (ROR). We identified 662, 744, and 1381 reports related to tocilizumab, lopinavir/ ritonavir, and hydroxychloroquine use, respectively. The RORs (95% confidence intervals) were 6.32 (5.28-7.56), 6.12 (5.22-7.17), and 9.07 (8.00-10.29), respectively, demonstrating an increased risk of liver events among patients with COVID-19 when compared with uninfected patients. The elevated risk of reporting adverse liver events in patients with COVID-19 who receive these drugs, alone or in combination, highlights the need for careful drug selection and efforts to reduce drug combinations without notable benefits. Similar to any other condition, the use of drugs without established efficacy should be avoided. 201 COVID19. COVID19 COVID 19 . (COVID-19) However alterations 19. COVID19, 19, them COVID-1 tocilizumab (tocilizumab remdesivir andor lopinavir/ritonavir, lopinavirritonavir lopinavir/ritonavir , lopinavir ritonavir lopinavir/ritonavir) 30 2020 FAERS (FAERS Dashboard ROR. ROR (ROR) 662 744 138 respectively 95% 95 (95 intervals 632 6 32 6.3 5.287.56, 528756 5.28 7.56 5 28 7 56 (5.28-7.56) 612 12 6.1 5.227.17, 522717 5.22 7.17 22 17 (5.22-7.17) 907 9 07 9.0 8.0010.29, 8001029 8.00 10.29 8 00 10 29 (8.00-10.29) combination benefits condition avoided 20 COVID1 1 (COVID-19 COVID- 3 202 (ROR 66 74 13 (9 63 6. 287 5.287.56 52875 528 5.2 756 7.5 2 (5.28-7.56 61 227 5.227.17 52271 522 717 7.1 (5.22-7.17 90 0 9. 0010 8.0010.29 800102 800 8.0 1029 10.2 (8.00-10.29 (COVID-1 ( 5.287.5 5287 52 5. 75 7. (5.28-7.5 5.227.1 5227 71 (5.22-7.1 001 8.0010.2 80010 80 8. 102 10. (8.00-10.2 (COVID- 5.287. (5.28-7. 5.227. (5.22-7. 8.0010. 8001 (8.00-10. (COVID 5.287 (5.28-7 5.227 (5.22-7 8.0010 (8.00-10 (5.28- (5.22- 8.001 (8.00-1 (5.28 (5.22 (8.00- (5.2 (8.00 (5. (8.0 (5 (8. (8